



NEONATAL MEDICATION GUIDELINE	
HEPATITIS B VACCINE	
Scope (Staff):	Nursing, Midwifery, Medical and Pharmacy Staff
Scope (Area):	KEMH NICU, PCH NICU, NETS WA, KEMH and OPH Postnatal Clinical Areas
This document should be read in conjunction with the Disclaimer .	

Quick Links

Dose	Preparation & Administration	Side Effects & Interactions	Monitoring
----------------------	--	---	----------------------------

Restrictions

[Formulary: Unrestricted](#)

Description

Hepatitis B surface antigen induces protective antibody against the Hepatitis B virus (Anti-HBs).
 For use as part of the National Immunisation Program for prevention of Hepatitis B infection.
 For use in infants born to Hepatitis B positive mothers.

NB: Parent/guardian consent is to be obtained prior to administration of all vaccinations

Presentation

Unit dose syringe: H-B-Vax II Paediatric Preservative-free 0.5mL (5 micrograms)

Unit dose syringe: ENGERIX-B Paediatric Thiomersal-free 0.5mL (10 micrograms)

The Engerix-B and H-B-Vax II vaccines are manufactured by different processes, and the hepatitis B surface antigen content of an 'equivalent' dose of these vaccines is different. Switching vaccine brands during the vaccine regimen is not recommended.

Storage

Refrigerate – do not freeze

Dose

Intramuscular: 0.5mL

For preterm infants <32 weeks of age and/or birth weight <2000g:

If infant's weight is less than 1000g - omit birth dose and give first dose at 2 months of age.

<u>Dose</u>	<u>Age</u>
1 st	At birth or no later than 7 days of age
2 nd	2 months
3 rd	4 months
4 th	6 months
5 th	12 months if antibody titre is low

All other infants:

<u>Dose Number</u>	<u>Age</u>
1 st	At birth or no later than 7 days of age
2 nd	2 months
3 rd	4 months
4 th	6 months

For Infants of Hepatitis B positive mothers on the day of birth:

IM hepatitis B Immunoglobulin 100 units should be administered in conjunction with Hepatitis B Vaccine.

Administer into the opposite thigh.

Administration

Intramuscular Injection

For administration by intramuscular injection ONLY

Administer the entire reconstituted vial volume (0.5 mL) by intramuscular injection (IMI) to the anterolateral aspect of the thigh (slowly to reduce pain).

Compatible Fluids

Do not combine with any other fluids or vaccinations

Side Effects

Common: Pain, redness or swelling at injection site, transient fever

Serious: allergic reactions including anaphylaxis

Monitoring

Observe all patients for at least 15 minutes after vaccination.

The potential risk of apnoea and the need for respiratory monitoring for 48-72 hours should be considered when administering the primary immunisation series to very premature infants (born \leq 28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.

Monitor temperature – Do not give during febrile illness or acute infection

Hepatitis B surface antigens and hepatitis B surface antibodies should be measured in infants born to mothers with chronic hepatitis B infection 3 to 12 months after completing the primary vaccine course.

Comments

Hepatitis B vaccine is a component of Infanrix hexa®, and is administered in this form at 2, 4 and 6 month doses.

Infanrix hexa® **must be reconstituted**. Add the entire contents of the syringe to the vial and shake until the pellet completely dissolves. Use reconstituted vaccine as soon as practicable. If it must be stored, hold at room temperature for no more than 8 hours.

Hepatitis B vaccine is recommended for all children. If the monovalent dose at birth is missed, vaccination against Hepatitis B should be continued with a multivalent vaccine following the routine schedule.

Hepatitis B Immunoglobulin is to be accessed from Pathology

Related Policies, Procedures & Guidelines

[National Immunisation Program Schedule](#)

[Western Australian Immunisation Schedule](#)

CAHS Clinical Practice Guidelines:

[Immunisations](#)

WNHS Clinical Practice Guidelines:

[Hepatitis B Virus \(HBV\): Care of the infant born to HBV positive women](#)

[Maternal Hepatitis B Virus \(HBV\) Quick Reference Guide](#)

[Vaccinations](#)

WNHS Transfusion Medicine Protocol:

[Immunoglobulin Products](#)









References

Australian Medicines Handbook. Hepatitis B vaccine. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 Nov 9]. Available from: <https://amhonline.amh.net.au/>

MIMS Australia. Engerix-B Vaccine paediatric formulation. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2016 [cited 2021 Nov 9]. Available from: <https://www.mimsonline.com.au>

MIMS Australia. H-B-Vax II paediatric formulation. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2016 [cited 2021 Nov 9]. Available from: <https://www.mimsonline.com.au>

The Australian Immunisation Handbook. Last updated October 2021 Available from: <https://immunisationhandbook.health.gov.au/vaccine-preventable-diseases/hepatitis-b>

Keywords	Hepatitis B, Engerix B, H-B-Vax II, vaccine, immunisation				
Document Owner:	Head of Department - Neonatology				
Author/ Reviewer	KEMH & PCH Pharmacy/Neonatology Directorate				
Version Info:	3.1				
Date First Issued:	Sep 2001	Last Reviewed:	Nov 2021	Review Date:	Nov 2024
Endorsed by:	Neonatal Directorate Management Group			Date:	22 Feb 2022
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2020

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.